



(43) International Publication Date
7 March 2013 (07.03.2013)

(10) International Publication Number
WO 2013/030167 A1

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/EP2012/066630

(22) International Filing Date:
28 August 2012 (28.08.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11179498.8 31 August 2011 (31.08.2011) EP

(71) Applicants (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH). **VIB vzw** [BE/BE]; Rijvisschestraat 120, B-9052 Gent (BE). **Life Sciences Research Partners vzw** [BE/BE]; Campus Gasthuisberg, Herestraat 49, bus 913, B-3000 Leuven (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DE HAAS, Sanne Lysbet** [NL/CH]; Wilhelm His-Strasse 1, CH-4056 Basel (CH). **DELMAR, Paul** [FR/CH]; Hammerstrasse 89, CH-4057 Basel (CH). **LAMBRECHTS, Diether** [BE/BE]; Ernest-Solvaystraat 55, B-3010 Kessel-lo (Leuven) (BE). **SCHERER, Stefan** [DE/US]; 1 DNA Way, South San Francisco, California 94080 (US).

(74) Agent: **BRODBECK, Michel**; Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: RESPONSIVENESS TO ANGIOGENESIS INHIBITORS

(57) Abstract: The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGF promoter gene and/or VEGFR2 gene.



WO 2013/030167 A1